Line 34: | Line 34: | ||
<img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300"> | <img src="https://static.igem.org/mediawiki/2017/9/97/T--CPU_CHINA--mainpage_new.png" width = "1300"> | ||
</center> | </center> | ||
− | + | ||
<center class="page page2"> | <center class="page page2"> | ||
+ | <h5>Our HEAD-Treg</h5> | ||
<video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "60%"></video> | <video src="https://static.igem.org/mediawiki/2017/1/14/T--CPU_CHINA--mainpagevideo.mp4" controls="controls" class="video" width = "60%"></video> | ||
</center> | </center> | ||
− | |||
− | + | <center class="page page3"><h3>Description</h3> | |
+ | <h4><br>Rheumatoid arthritis (RA) is a serious chronic, inflammatory and systemic autoimmune disease. | ||
<br>It is of great essence to develop a novel cell-targeted therapy for RA | <br>It is of great essence to develop a novel cell-targeted therapy for RA | ||
because there is no radical cure | because there is no radical cure | ||
Line 46: | Line 47: | ||
<br>Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the | <br>Meanwhile, we insert the Syn-Notch receptor to activate the functional stability pathway of Tregs in the | ||
inflammatory environment, which enables them to play their role of immunosuppression in lesions more | inflammatory environment, which enables them to play their role of immunosuppression in lesions more | ||
− | efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4></center> | + | efficiently and more stably. <br>These two redirections of the two different but interrelated systems on Tregs ensure this novel therapy a promising anti-RA effect. </h4> |
+ | </center> | ||
</div> | </div> |
Revision as of 12:04, 1 November 2017